BNT162b2 (COMIRNATY)

BLA STN 125742/0

Response to CBER 22 July 2021 Information Request Regarding Clinical Shell Tables for Study C4591001

Follow-Up #1

July 2021

TABLE OF CONTENTS

1. INTRODUCTION

Reference is made to BLA STN 125742/0 for COVID-19 mRNA Vaccine (COMIRNATY), for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals ≥16 years of age and to CBER's 22 July 2022 Information Request received via email from Laura Gottshalk, PhD (CBER) regarding clinical shell tables for Study C4591001.

Further reference is made to the Response to CBER 22 July 2021 Information Request submitted to BLA 125549/0 on 26 July 2021.

Please note the following:

- Responses to CBER 22 July 2021 Information Request Items 3, 4, 5, 7, 8 and 9 were submitted to BLA 125549/0 on 26 July 2021.
- This first follow-up Response addresses CBER 22 July 2021 Information Request Items 1 and 2.
- CBER 22 July 2021 Information Request Item 6 will be the subject of separate, future, follow-up Response that will be submitted by 13 August 2021 (as indicated in the 28 July 2021 submission).

CBER requests are provided below in ***bold italics*** with Sponsor responses in plain text.

2. CBER INFORMATION REQUESTS AND SPONSOR RESPONSES

2.1. CBER Request 1

Please provide the number and percentage of clinical COVID cases that meet the case definition but not confirmed by PCR for any reason (e.g., not done, sample lost, out of window), by study arm.

Sponsor Response

The requested information is provided in Table 1 and Table 2.

Table 1. Subjects With Symptoms of COVID-19 but not Confirmed Cases by PCR – Subjects With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

	Vaccine Group (as Randomized)		
	BNT162b2 (30 µg) n[a](%)	Placebo n[a](%)	Total n[a](%)
Subjects developed protocol defined symptoms after 7 days post dose 2 but not confirmed cases by PCR[b]	2285	2646	4931
PCR Results Negative	2026 (88.7)	2305 (87.1)	4331 (87.8)
PCR Results unavailable or unknown	303 (13.3)	396 (15.0)	699 (14.2)
Swab not taken	210 (9.2)	267 (10.1)	477 (9.7)
Swab taken but results not available	13 (0.6)	41 (1.5)	54 (1.1)
Swab taken outside of symptom window	80 (3.5)	88 (3.3)	168 (3.4)

Note: If a subject develops unconfirmed protocol defined symptoms multiple times, they may be classified under both negative and unavailable or unknown rows depending on the status of swab associated with each illness.
a. n = Number of subjects with the specified characteristic.
b. The values in this row are the denominators for the percentage calculations.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adsympt Table Generation: 26JUL2021 (12:49)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA_RR/adsympt_sympt_pcr_7pd2_eval

Table 2. Subjects With Symptoms of COVID-19 but not Confirmed Cases by PCR – Subjects Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

	Vaccine Group (as Randomized)		
	BNT162b2 (30 µg) n[a](%)	Placebo n[a](%)	Total n[a](%)
Subjects developed protocol defined symptoms after 7 days post dose 2 but not confirmed cases by PCR[b]	2164	2513	4677
PCR Results Negative	1926 (89.0)	2194 (87.3)	4120 (88.1)
PCR Results unavailable or unknown	279 (12.9)	369 (14.7)	648 (13.9)
Swab not taken	192 (8.9)	248 (9.9)	440 (9.4)
Swab taken but results not available	13 (0.6)	37 (1.5)	50 (1.1)
Swab taken outside of symptom window	74 (3.4)	84 (3.3)	158 (3.4)

Note: If a subject develops unconfirmed protocol defined symptoms multiple times, they may be classified under both negative and unavailable or unknown rows depending on the status of swab associated with each illness.
a. n = Number of subjects with the specified characteristic.
b. The values in this row are the denominators for the percentage calculations.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adsympt Table Generation: 26JUL2021 (12:49)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA_RR/adsympt_sympt_pcr_7pd2_wo_eval

2.2. CBER Request 2

Please provide the cumulative incidence rates for the vaccine group as compared to the placebo group at 2, 4, and 6 months post dose 1 to complement the cumulative incidence curve submitted (Figure 2, pg 104, from c4591001-interim-mth6-report-body.pdf).

Sponsor Response

The requested information is provided in Table 3.

Table 3. Cumulative Incidence of COVID-19 Occurrence After Dose 1 – Blinded Placebo-Controlled Follow-up Period – Dose 1 All-Available Efficacy Population

	Vaccine Group (as Randomized)	
	BNT162b2 (30 µg)	Placebo
Efficacy Endpoint	Cumulative Incidence of COVID-19 Occurrence[a]	Cumulative Incidence of COVID-19 Occurrence[a]
First COVID-19 occurrence upto 2 Months after Dose 1	0.0024	0.0139
First COVID-19 occurrence upto 4 Months after Dose 1	0.0041	0.0358
First COVID-19 occurrence upto 6 Months after Dose 1	0.0076	0.0601

a. Cumulative Incidence of COVID-19 Occurrence is derived based on the Kaplan-Meier Method.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:19) Source Data: adc19ef Table Generation: 23JUL2021 (15:54)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA_RR/adc19ef_kmci_pd1

Document Approval Record

Document Name:	COVID-19 Vaccine 1st Follow-Up Response to CBER 22 July 2021 Info Request RE Clinical Shell Tables for Study C4591001
Document Title:	COVID-19 Vaccine 1st Follow-Up Response to CBER 22 July 2021 Info Request RE Clinical Shell Tables for Study C4591001

Signed By:	Date(GMT)	Signing Capacity
Perez, John	27-Jul-2021 18:04:42	Final Approval
Koury, Kenneth	27-Jul-2021 19:43:45	Final Approval